Intellia Therapeutics

Intellia Therapeutics (NTLA) is the lead sponsor of 6 active clinical trials listed on ClinicalTrials.gov^[4], including 3 Phase 3^[1], 1 Phase 2^[2], 1 Phase 1^[3].

Trial NCT06634420^[5] evaluates NTLA-2002 in Hereditary Angioedema with a target enrollment of 60 participants. Trial NCT06672237^[6] evaluates nexiguran ziclumeran in Neuromuscular Disease with a target enrollment of 50 participants. Trial NCT06128629^[7] evaluates NTLA-2001 in Transthyretin Amyloidosis (ATTR) With Cardiomyopathy with a target enrollment of 1200 participants.

No Form 4 insider filings for NTLA were recorded at the SEC in the past 30 days^[8].